Financials disclosed in this offering
FY2022–FY2023 · hover for sourceThe fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.
Amendments to this offering
4 amendments- Aug 27, 2025
- Deadline Aug 28, 2025 → Sep 29, 2025
“Issuer is updating their offering end date to September 29, 2025.”
Form C/A on EDGAR ↗ - Aug 14, 2025
- Jun 17, 2025
- Deadline Jun 17, 2025 → Aug 28, 2025
“Issuer is extending their end date to August 28th, 2025, disclosing the acquisition of Alpha Anomeric SA, and disclosing the appointment of Lance Hirsch.”
Form C/A on EDGAR ↗ - Mar 18, 2025
- Deadline Apr 30, 2025 → Jun 17, 2025
- Maximum $1.2M → $5M
- Target $124K → $20K
“Audited financials for FY 12/31/24 & 12/31/23 completed; prior year adjusted. Cash on hand updated to Feb 2025. Added disclosures on product status, FDA process, IP, insider investments ($6,199.20), funding goals, use of proceeds & extended end date.”
Form C/A on EDGAR ↗
Each line compares the amendment with the previous filing of this offering. The quoted reason is the issuer’s own statement from the Form C/A.
Deal terms
Perks
Offering details
Links & provenance
0001665160-25-000154
Last synced Aug 18, 2026
About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.